Skip to content
beroni logo newberoni logo new
  • About
    • About Beroni
    • Our History
    • Board of Directors
    • Management Team
    • Vision, Mission and Values
  • R&D
  • Core Businesses
    • Cell Therapies
    • Anti-Cancer Drugs
    • Infectious Diseases
    • Infectious Diseases – COVID-19
    • E-commerce
  • Products
    • By Beroni China
    • By Beroni USA
    • By Beroni Biotech
  • Investors
    • Announcements
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Globenewswire Press Releases
    • Medtech Outlook
    • Research Report
    • COVID-19 Vaccines Overview
    • FAQs
  • News
  • Contact
  • English
    • 简体中文
Menu Close

2020 Press Releases

Date

Title

10/11/2020

Beroni Group Launches a New Probiotics Health Product in China

09/11/2020

Beroni Group Named as a Top Infection Control Solutions Company in APAC for 2020

19/10/2020

Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19

08/09/2020

Beroni Group Receives First Commercial Order for its COVID-19 Test Kits from Japan

12/08/2020

Beroni Signs Agreement with Genscript Biotech

04/08/2020

Beroni Constructed Nanobodies for Coronavirus

10/07/2020

Beroni to Supply COVID-19 Antibody Test Kit to Japan

30/06/2020

Dr Richard Buchta Appointed as Director of Beroni Group

27/05/2020

Issue of US$2.97m Convertible Notes to Fund Growth

08/05/2020

Beroni Identifies 24 Types of Nanobodies for COVID-19

03/04/2020

CE Certification Received for Covid-19 Test Kit

03/04/2020

Beroni Notifies FDA of Validated COVID19 Serology Test

26/03/2020

Submission of COVID-19 Rapid Test Kit to US FDA

09/03/2020

Beroni Advances R&D of Medical Solution for COVID-19

20/02/2020

Beroni to Develop Novel Solution for Coronavirus

12/02/2020

Beroni Featured in New Research Initiation Report

14/01/2020

Beroni Group Announces Webcast from Biotech Showcase™ 2020 in San Francisco

13/01/2020

Beroni Group to Present at Biotech Showcase™ 2020 in San Francisco

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the USA with business presence in Australia, China, Japan and the USA. It currently has four core businesses – research and development of new drugs and clinical trial, immune cell therapy including gene detection and diagnosis, immunotherapy for cancer treatment, diagnosis of infectious diseases and e-commerce based on the Internet sales of pharmaceutical, healthcare and cosmetic products.

About

  • About Beroni
  • Our History
  • Board of Directors
  • Management Team
  • Vision, Mission, and Values

Core Businesses

  • Cell Therapy
  • Anti-Cancer Drugs
  • Infectious Diseases
  • E-Commerce

Products

  • By Beroni China
  • By Beroni Japan
  • By Beroni USA

Copyrights© Beroni Group 2019 | All rights reserved |

website by chase e-Design

Close Menu